Stifel lowered the firm's price target on Viridian Therapeutics to $39 from $48 and keeps a Buy rating on the shares. The firm has modeled a slower franchise ramp and reallocated share between Veligrotug and Elegrobart across active and chronic thyroid eye disease, the analyst tells investors.
